Geschäftsbericht der Lindenhofgruppe 2019

Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperations- partner /  Sponsor A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Pf-06651600 and Pf-06700841 as Induction and Open Label Extension Treatment in Subjects With Moderate to Severe Crohn’s Disease (Pfizer Icon B7981007_Pizzicato_1125_MC) Gastroenterologie Prof. Dr. med. Frank Seibold Pfizer A Phase III, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn’s Disease (ETRO_144) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann- La Roche/ Genentech An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn’s Disease Previously Enrolled in the Etrolizumab Phase III (ETRO_145) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann- La Roche/ Genentech Phase III, Double-Blind, Placebo-controlled, Multicenter Study of the Efficacy And Safety of Etrolizumab during Induc- tion and Maintenance in Patients with Moderate to Severe Active Ulcerative Colitis who have been Previously Exposed to TNF Inhibitors (ETRO_950) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann- La Roche/ Genentech An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies (ETRO_951) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann- La Roche/ Genentech A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirkizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severly Active Ulcerative Colitis LUCENT 1 (AMAN_Induction_Eli Lilly_CU) Gastroenterologie Prof. Dr. med. Frank Seibold Eli Lilly SIBDCS Cohort Beobachtungsstudie: Die Swiss IBD Cohort Study ist ein Zusammenschluss von Ärztinnen/Ärzten und Wissenschaftlern, mit dem Ziel, chronisch entzündliche Darmerkrankungen besser zu verstehen Gastroenterologie Prof. Dr. med. Frank Seibold Schweizer Nationalfonds Biomarkers in the secretome of preeclamptic patients: a novel approach for data mining on the maternal-fetal interface Gynäkologie und Geburtshilfe Dr. med. Ruedi Moser-Hässig Institut für Bio- chemie und Mo- lekulare Medizin der Universität Bern Geschäftsbericht 2019 74 Lehre und Forschung